A Phase Ib, Open-Label, Two Arm Study of i.v. and Oral Panobinostat (LBH589) in Combination With i.v. Trastuzumab (Herceptin) and i.v. Paclitaxel as Treatment for Adult Female Patients With HER2 Overexpressing Metastatic Breast Cancer (MBC).

Trial Profile

A Phase Ib, Open-Label, Two Arm Study of i.v. and Oral Panobinostat (LBH589) in Combination With i.v. Trastuzumab (Herceptin) and i.v. Paclitaxel as Treatment for Adult Female Patients With HER2 Overexpressing Metastatic Breast Cancer (MBC).

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2012

At a glance

  • Drugs Panobinostat (Primary) ; Panobinostat (Primary) ; Paclitaxel; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 03 May 2012 Trial phase changed from I/II to I as reported by ClinicalTrials.gov.
    • 03 May 2012 Additional locations identified as reported by ClinicalTrials.gov.
    • 03 May 2012 Actual patient number changed from 13 to 15 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top